Novel immunocytokine utilizes dual mechanisms of action to activate immune system to fight solid tumors Company has received IND and CTA approval to initiate Phase 1 study in the U.S. and
Patient enrollment and dosing ongoing in first-in-human study of BOXR1030 enhanced CAR T-cell therapy SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, will present
SOTIO Biotech: SOTIO to Present Poster on DUET-01 Clinical Trial at 2024 ASCO Annual Meeting finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
SOTIO Biotech: SOTIO Presents New Preclinical Data on Enhanced CAR T-Cell Therapies at AACR Annual Meeting finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
SOTIO Biotech: SOTIO Presents Data on SOT201 Immunocytokine and Other Programs at SITC Annual Meeting finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.